MedTrace Logo

Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers

NCT02291471 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-07-09

No results posted yet for this study

Summary

The purpose of this study to assess the MTD and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers.

Conditions

  • Rheumatic Diseases

Interventions

DRUG

T0001，10mg

DRUG

T0001，20mg

DRUG

T0001，35mg

DRUG

T0001，50mg

DRUG

T0001，65mg

DRUG

T0001，75mg

Sponsors & Collaborators

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wang wei · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

  • Fang Yi, Ph.D · Peking University People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02291471 on ClinicalTrials.gov